New obesity drug tested for safety and drug interactions
NCT ID NCT07128888
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This early-stage study tests an experimental injection called GZR18 in 60 overweight or obese adults. The goal is to see how it affects stomach emptying and whether it changes how common medications like digoxin, rosuvastatin, and warfarin work in the body. Participants will receive the injection and take these oral drugs in a fixed order over about 26 weeks to check for interactions and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY OR OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study site 01
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.